Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Terazosin Target Engagement in Healthy Adults
NCT04551040Phase 1Active, not recruiting
- Sponsor
- University of Iowa
- Start
- Mar 2021
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of terazosin in Parkinson's disease (PD), sponsored by University of Iowa. Primary endpoints: Quantification of glycolysis in the brain at baseline at Day 1, Change in glycolysis in the brain from baseline to 1 week and 8 more. Started Mar 2021; status: active, not recruiting.
02
Drugs
terazosin
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04551040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551040.